Document Type
Article
Publication Date
2020
Abstract
Obese patients are more likely to suffer from severe asthma symptoms and less likely to be able to control them. In obese patients, there is evidence that shows decreased efficacy of inhaled corticosteroids and beta-2 adrenergic agonists, the core treatment options for achieving and maintaining asthma control. This may be due to mechanical reasons like decreased ventilation and medication delivery, but there are many more pathologies of obesity that interact with pathways of both asthma pathology and asthma control. This review explores the epidemiological significance of obesity, many physiological changes in patients with obesity, the physiological interactions of asthma and obesity in patients with both issues, and the therapeutic impacts of these interactions with asthma to find appropriate areas where new research is needed. More research to understand the mechanism of decreased inhaled corticosteroid and beta-2 adrenergic agonist efficacy is necessary to improve treatment efficacy and decrease morbidity and mortality in this population of patients with asthma.
Recommended Citation
Magagna, John; Loblundo, Cali; Penn, Raymond B.; Deshpande, Deepak A.; and Nayak, Ajay P., "Obesity and Obstructive Airways Disease: Clinical Correlates and Therapeutic Considerations" (2020). Student Papers, Posters & Projects. Paper 65.
https://jdc.jefferson.edu/student_papers/65
Language
English
Comments
This paper was written in conjunction with the SKMC Scholarly Inquiry project, Effect of Palmitic Acid on B2 Receptor Expression In Airway Smooth Muscle Cells.